Conisation as a marker of persistent human papilloma virus infection and risk of breast cancer

Background: Human papillomavirus (HPV) infection may increase breast cancer (BC) risk. Methods: To examine this, we used nationwide medical registries to identify all Danish women who underwent conisation to remove HPV-associated cervical precancerous lesions ( n =87 782) from 1978 to 2013. We compu...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2016-08, Vol.115 (5), p.588-591
Main Authors: Søgaard, Mette, Farkas, Dora K, Ording, Anne G, Sørensen, Henrik T, P Cronin-Fenton, Deirdre
Format: Article
Language:English
Subjects:
631/326/596/2560
692/499
692/699/255/2514
692/699/67/1347
Adult
Age
Alcohol
Autoimmune diseases
Biomedical and Life Sciences
Biomedicine
Breast cancer
Breast Neoplasms - complications
Cancer Research
Comorbidity
Conization
Denmark
Disease
Drug Resistance
Emigration
Epidemiology
Female
Health services
Human papillomavirus
Humans
Infections
Medical research
Molecular Medicine
Obesity
Oncology
Papillomavirus Infections - complications
Papillomavirus Infections - epidemiology
Risk Factors
Short Communication
Tumors
Uterine Cervical Neoplasms - complications
Uterine Cervical Neoplasms - therapy
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Human papillomavirus (HPV) infection may increase breast cancer (BC) risk. Methods: To examine this, we used nationwide medical registries to identify all Danish women who underwent conisation to remove HPV-associated cervical precancerous lesions ( n =87 782) from 1978 to 2013. We computed the absolute risk of BC and standardised incidence ratios (SIRs) and 95% confidence intervals (95% CIs) for breast cancer, based on national breast cancer incidence rates. Results: Conisation was associated with slightly increased BC incidence (SIR=1.1, 95% CI=1.0–1.1), and an absolute BC risk of 7.7% (95% CI=7.3–8.1%) in 35.9 years of follow-up. BC risk was elevated throughout follow-up, especially in the first 5 years (
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.2016.150